- Home
- ERAS vs BALY Comparison
ERAS vs BALY Comparison
Compare ERAS & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- BALY
- Stock Information
- Founded
- ERAS 2018
- BALY 2004
- Country
- ERAS United States
- BALY United States
- Employees
- ERAS N/A
- BALY N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- ERAS Health Care
- BALY Consumer Discretionary
- Exchange
- ERAS Nasdaq
- BALY Nasdaq
- Market Cap
- ERAS 719.0M
- BALY 709.6M
- IPO Year
- ERAS 2021
- BALY N/A
- Fundamental
- Price
- ERAS $2.67
- BALY $17.80
- Analyst Decision
- ERAS Strong Buy
- BALY Hold
- Analyst Count
- ERAS 5
- BALY 7
- Target Price
- ERAS $6.10
- BALY $18.00
- AVG Volume (30 Days)
- ERAS 1.7M
- BALY 457.4K
- Earning Date
- ERAS 11-12-2024
- BALY 11-06-2024
- Dividend Yield
- ERAS N/A
- BALY N/A
- EPS Growth
- ERAS N/A
- BALY N/A
- EPS
- ERAS N/A
- BALY N/A
- Revenue
- ERAS N/A
- BALY $2,481,783,000.00
- Revenue This Year
- ERAS N/A
- BALY $3.55
- Revenue Next Year
- ERAS N/A
- BALY $1.38
- P/E Ratio
- ERAS N/A
- BALY N/A
- Revenue Growth
- ERAS N/A
- BALY 2.80
- 52 Week Low
- ERAS $1.51
- BALY $9.74
- 52 Week High
- ERAS $3.45
- BALY $18.00
- Technical
- Relative Strength Index (RSI)
- ERAS 43.56
- BALY 71.13
- Support Level
- ERAS $2.59
- BALY $17.76
- Resistance Level
- ERAS $3.19
- BALY $17.97
- Average True Range (ATR)
- ERAS 0.20
- BALY 0.10
- MACD
- ERAS -0.02
- BALY 0.02
- Stochastic Oscillator
- ERAS 20.13
- BALY 71.31
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About BALY Bally's Corporation
Ballys Corp is a casino entertainment company with a growing omni-channel presence. It currently owns and manages 15 casinos across 10 states, a golf course in New York, a horse racetrack in Colorado, and has access to OSB licenses in 18 states. It also owns Bally's Interactive International, formerly Gamesys Group, a online gaming operator, Bally Bet, a sports betting platform, and Bally Casino, a iCasino platform. The Company's casino operations include approximately 15,300 slot machines, 580 table games, and 3,800 hotel rooms.